Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer
Status:
Completed
Trial end date:
2014-10-07
Target enrollment:
Participant gender:
Summary
More than 50% of Head and Neck cancers are locally advanced at presentation. Although
surgery, in combination with other modalities like radiation therapy can achieve 40-50% five
year survival rates, resection in the head and neck region can leave patients with poor
functional and cosmetic outcomes.
Due to these concerns about quality of life after surgery, there has been a lot of interest
in non surgical alternatives of treatment. Various combinations of radiation, chemotherapy
and biologics has showed promising results. However, questions still remain about the ideal
combination treatment regimen.
Based on assimilation of data from multiple sources, our study tries to identify the role of
a potentially highly effective multi-modality regimen based on induction chemotherapy
(Cisplatin, Docetaxel and 5 Fluorouracil) followed by combination of a biologic agent,
Cetuximab, and radiation therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Drexel University Drexel University College of Medicine